Evidence map›Paper›PMID 37755689›Full record

ArticleDermatology and therapy2023

Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry.

Robert R McLean, Adam P Sima, Silky Beaty, Robert Low, Rebecca L Spitzer, Jeffrey L Stark, Elizabeth Lesser, Edward Lee, April Armstrong

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02707341 (CorEvitas Psoriasis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02707341 recruitingnot on this map

CorEvitas Psoriasis (PSO) Registry

Typeobservational_patient_registrySponsorCorEvitasRan2015 to 2100Enrolled10,000ConditionsPsoriasis
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Robert R McLeanCorEvitas, LLC, 1440 Main St, Waltham, MA, 02130, USA. rmclean@corevitas.com.
Adam P SimaCorEvitas, LLC, 1440 Main St, Waltham, MA, 02130, USA.
Silky BeatyUCB Pharma, Smyrna, GA, USA.
Robert LowUCB Pharma, Smyrna, GA, USA.
Rebecca L SpitzerCorEvitas, LLC, 1440 Main St, Waltham, MA, 02130, USA.
Jeffrey L StarkUCB Pharma, Smyrna, GA, USA.
Elizabeth LesserCorEvitas, LLC, 1440 Main St, Waltham, MA, 02130, USA.
Edward LeeUCB Pharma, Smyrna, GA, USA.
April ArmstrongKeck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
Navitas Systems (United States) · USUCB Pharma (United States) · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionComplete and near-complete skin clearance have become achievable treatment goals for patients with psoriasis receiving systemic biologic therapies. However, there is limited real-world evidence regarding the impact of the degree of skin clearance on biologic treatment patterns among these patients.

methodsThis longitudinal cohort study assessed the relationship between degree of skin clearance following initiation of a systemic biologic therapy and treatment failure among patients from the CorEvitas Psoriasis Registry (April 2015-August 2021). Patients had Psoriasis Area and Severity Index (PASI) score > 5 at systemic biologic therapy initiation and ≥ 1 follow-up visit(s) within 15 months of initiation. Treatment failure (discontinuation due to poor response/adverse event; addition of non-biologic therapy) and degree of skin clearance (measured by PASI) were assessed following biologic initiation. Proportional hazards regression was used to estimate the association between PASI response level and treatment failure over follow-up.

resultsThis study included 2701 patient initiations from 2516 unique patients with 3846 total visits over follow-up. Over half of the patient initiations (n = 1412; 52.3%) were among patients with PASI >10. Treatment failure occurred in 1.3% of visits at which PASI100 was achieved, while those achieving PASI90 - < 100 and PASI75 - < 90 had treatment failure rates of 3.4% and 3.5%, respectively. After adjustment for confounders, the risk of treatment failure was two to three times higher in the PASI90 - < 100 (hazard ratio [HR] = 2.61; 95% confidence interval [CI] 1.35, 5.02; p = 0.004) and PASI75 < 90 (HR = 2.97; CI 1.58, 5.58; p = 0.001) groups compared to the PASI100 group. The risk of treatment failure was more than 20 times higher in the < PASI75 group versus the PASI100 group (HR = 22.26; CI 13.32, 37.21; p < 0.001).

conclusionsThe results suggest that patients are more likely to remain on a systemic biologic therapy if they achieve near-complete or complete skin clearance, supporting the continued need to target skin clearance as a treatment goal in psoriasis.

trial registrationClinicalTrials.gov identifier, NCT02707341.

Indexed as

Biologic therapyCorEvitas Psoriasis RegistryPASIPsoriasisReal-world evidenceSkin clearanceTreatment failure

Identifiers

PMID37755689
PMCPMC10613186
OpenAlexW4387077404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.